982 related articles for article (PubMed ID: 29223444)
21. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
22. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Rosario M; Dirks NL; Milch C; Parikh A; Bargfrede M; Wyant T; Fedyk E; Fox I
Clin Pharmacokinet; 2017 Nov; 56(11):1287-1301. PubMed ID: 28523450
[TBL] [Abstract][Full Text] [Related]
23. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
25. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.
Steenholdt C; Lorentsen RD; Petersen PN; Widigson ES; Kloft C; Klaasen RA; Brynskov J
J Gastroenterol Hepatol; 2024 Jun; 39(6):1088-1098. PubMed ID: 38380724
[TBL] [Abstract][Full Text] [Related]
27. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
28. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
Van den Berghe N; Verstockt B; Tops S; Ferrante M; Vermeire S; Gils A
J Gastroenterol Hepatol; 2019 Jul; 34(7):1175-1181. PubMed ID: 30589948
[TBL] [Abstract][Full Text] [Related]
31. The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
Abraham BP; Fan C; Thurston T; Moskow J; Malaty HM
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004241
[TBL] [Abstract][Full Text] [Related]
32. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
33. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
34. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
Schulze H; Esters P; Hartmann F; Stein J; Christ C; Zorn M; Dignass A
Scand J Gastroenterol; 2018 Jun; 53(6):670-676. PubMed ID: 29560811
[TBL] [Abstract][Full Text] [Related]
35. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
36. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
Wittner M; Schlicker V; Libera J; Bockmann JH; Horvatits T; Seiz O; Kummer S; Manthey CF; Hüfner A; Kantowski M; Rösch T; Degen O; Huber S; Eberhard JM; Schulze Zur Wiesch J
PLoS One; 2019; 14(7):e0220008. PubMed ID: 31356607
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.
Kopylov U; Avni-Biron I; Ron Y; Koslowsky B; Waterman M; Daher S; Ungar B; Schwartz D; Zittan E; Openhaim M; Yanai H; Maharshak N; Bar Gil Shitrit A; Naftali T; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Dig Liver Dis; 2019 Jan; 51(1):68-74. PubMed ID: 30172649
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy.
Abreu MT; Davies JM; Quintero MA; Delmas A; Diaz S; Martinez CD; Venables T; Reich A; Crynen G; Deshpande AR; Kerman DH; Damas OM; Fernandez I; Santander AM; Pignac-Kobinger J; Burgueno JF; Sundrud MS
Inflamm Bowel Dis; 2022 Dec; 28(12):1800-1812. PubMed ID: 35993552
[TBL] [Abstract][Full Text] [Related]
40. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
